DNA methylation heterogeneity correlates with field cancerization and prognosis in lung adenocarcinoma patients

被引:0
作者
Zhou, Ying [1 ]
Zhang, Jing [1 ]
He, Yang [2 ]
Wang, Yun [1 ]
Li, Bing [3 ]
Zhu, Tengfei [3 ]
Su, Yanjun [4 ]
机构
[1] Tianjin Canc Hosp Airport Hosp, Dept Integrat Oncol, Tianjin, Peoples R China
[2] Tianjin Canc Hosp Airport Hosp, Dept Breast Canc, Tianjin, Peoples R China
[3] Burning Rock Biotech, Guangzhou, Peoples R China
[4] Tianjin Canc Hosp Airport Hosp, Dept Thorac Oncol, 99 Dongwudao Rd, Tianjin 300308, Peoples R China
关键词
Lung adenocarcinoma; DNA methylation; Field cancerization; Calcium signaling; P2RX2; PROMOTER METHYLATION; RAR-BETA; CANCER; CDO1; HYPERMETHYLATION; IDENTIFICATION; PROGRESSION; RECURRENCE; CALCIUM; CDKN2A;
D O I
10.1186/s13148-025-01845-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundLung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer. The distinctive genetic and epigenetic modifications in tumors and paired non-malignant samples, such as adjacent peri-tumor and tumor-distant normal lung tissues, have not been adequately studied.MethodsWe recruited 57 patients with resectable stage I-III LUAD and collected matched samples of the primary tumor, peri-tumoral tissues, and tumor-distant normal lung tissue. We performed bisulfite sequencing using a custom methylation panel to profile DNA methylation levels and obtained somatic variation landscape through targeted next-generation sequencing (NGS). We attempted to identify differential methylation blocks (DMBs) between the tumor, peri-tumor, and normal tissues.ResultsWe analyzed the DNA methylation patterns of matched tumor, peri-tumor, and normal lung tissue samples from 57 LUAD patients. No significantly different methylation blocks were found between peri-tumoral and normal tissues, while they both exhibited distinct methylation profiles compared to tumor tissues. A total of 1329 tumor-specific DMBs, which are potentially associated with aberrant gene expression in LUAD, were identified. Utilizing a consensus clustering algorithm, we classified the tumor samples into two subgroups (C1 and C2) based on distinct methylation profiles, independent of the patient's sex, tumor stage, smoking history, and tumor cell fraction. The C2 subgroup exhibited a higher malignancy density ratio (MD ratio), suggesting a more pronounced degree of field cancerization, while the C1 subgroup was characterized by a higher frequency of EGFR mutations. The DMBs between the two subgroups were enriched in the calcium signaling pathway. Notably, P2RX2 shows significant hypermethylation in the C2 subgroup, and its low expression in the external The Cancer Genome Atlas (TCGA) cohort may correlate with reduced overall survival in LUAD patients.ConclusionOur findings revealed distinct methylation patterns between tumor and pre-malignant samples, such as peri-tumor and normal tissues. Moreover, our study suggests that distinct clustering based on DNA methylation may indicate different prognoses in LUAD patients.
引用
收藏
页数:12
相关论文
共 58 条
  • [1] Down-expression of P2RX2, KCNQ5, ERBB3 and SOCS3 through DNA hypermethylation in elderly women with presbycusis
    Bouzid, Amal
    Smeti, Ibtihel
    Dhouib, Leila
    Roche, Magali
    Achour, Imen
    Khalfallah, Aida
    Gibriel, Abdullah Ahmed
    Charfeddine, Ilhem
    Ayadi, Hammadi
    Lachuer, Joel
    Ghorbel, Abdelmonem
    Petit, Christine
    Masmoudi, Saber
    [J]. BIOMARKERS, 2018, 23 (04) : 347 - 356
  • [2] Cysteine Dioxygenase 1 Is a Tumor Suppressor Gene Silenced by Promoter Methylation in Multiple Human Cancers
    Brait, Mariana
    Ling, Shizhang
    Nagpal, Jatin K.
    Chang, Xiaofei
    Park, Hannah Lui
    Lee, Juna
    Okamura, Jun
    Yamashita, Keishi
    Sidransky, David
    Kim, Myoung Sook
    [J]. PLOS ONE, 2012, 7 (09):
  • [3] Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Bray, Freddie
    Laversanne, Mathieu
    Sung, Hyuna
    Ferlay, Jacques
    Siegel, Rebecca L.
    Soerjomataram, Isabelle
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2024, 74 (03) : 229 - 263
  • [4] A systematic review and meta-analysis: Association between MGMT hypermethylation and the clinicopathological characteristics of non-small-cell lung carcinoma
    Chen, Lin
    Wang, Yong
    Liu, Fen
    Xu, Liyao
    Peng, Feifei
    Zhao, Ning
    Fu, Biqi
    Zhu, Zijie
    Shi, Yu
    Liu, Jiansheng
    Wu, Renrui
    Wang, Chen
    Yao, Shengmin
    Li, Yong
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [5] Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
    Chen, Xi
    Fang, Liangjie
    Zhu, Yanping
    Bao, Zhang
    Wang, Qing
    Liu, Rong
    Sun, Wenjia
    Du, Haiwei
    Lin, Jing
    Yu, Bing
    Chen, Songan
    Zhou, Jianya
    Zhou, Jianying
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (12) : 3513 - 3524
  • [6] An evolutionary perspective on field cancerization
    Curtius, Kit
    Wright, Nicholas A.
    Graham, Trevor A.
    [J]. NATURE REVIEWS CANCER, 2018, 18 (01) : 19 - 32
  • [7] RARβ Promoter Methylation as an Epigenetic Mechanism of Gene Silencing in Non-small Cell Lung Cancer
    Dutkowska, A.
    Antczak, A.
    Pastuszak-Lewandoska, D.
    Migdalska-Sek, M.
    Czarnecka, K. H.
    Gorski, P.
    Kordiak, J.
    Nawrot, E.
    Brzezianska-Lasota, E.
    [J]. ADVANCES IN CLINICAL SCIENCE, 2016, 878 : 29 - 38
  • [8] The Epigenetic Hallmarks of Cancer
    Esteller, Manel
    Dawson, Mark A.
    Kadoch, Cigall
    Rassool, Feyruz V.
    Jones, Peter A.
    Baylin, Stephen B.
    [J]. CANCER DISCOVERY, 2024, 14 (10) : 1783 - 1809
  • [9] Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
  • [10] Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis
    Fang, Li Tai
    Lee, Sharon
    Choi, Helen
    Kim, Hong Kwan
    Jew, Gregory
    Kang, Hio Chung
    Chen, Lin
    Jablons, David
    Kim, Il-Jin
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 44 (01) : 211 - 221